Article
Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.
The New England journal of medicine - 16 Mar 2023
Egbuna Ogo, Zimmerman Brandon, Manos George, Fortier Anne, Chirieac Madalina C, Dakin Leslie A, Friedman David J, Bramham Kate, Campbell Kirk, Knebelmann Bertrand, Barisoni Laura, Falk Ronald J, Gipson Debbie S, Lipkowitz Michael S, Ojo Akinlolu, Bunnage Mark E, Pollak Martin R, Altshuler David, Chertow Glenn M
Abstract excerpt
BACKGROUND: Persons with toxic gain-of-function variants in the gene encoding apolipoprotein L1 (APOL1) are at greater risk for the development of rapidly progressive, proteinuric nephropathy. Despite the known genetic cause, therapies targeting proteinuric kidney disease in persons with two APOL1 variants (G1 or G2) are lacking. METHODS: We used tetracycline-inducible APOL1 human embryonic kidney (HEK293) cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.